Filing and reporting period
Important identification mismatch: The supplied filing is AntriaBio, Inc.’s Form 10-K for the fiscal year ended June 30, 2014, not a Rezolute, Inc. filing or a report for 2013 Q4. The company describes itself as a preclinical-stage therapeutics developer; its lead candidate was AB101, a proposed once-weekly basal insulin. The financial statements compare fiscal 2014 with fiscal 2013.
Financial results and liquidity
| Metric | FY ended June 30, 2014 | FY ended June 30, 2013 |
|---|---|---|
| Revenue | None | None |
| Operating expenses | $5.18 million | $6.11 million |
| Operating loss | $5.18 million | $6.11 million |
| Interest expense | $4.23 million | $0.57 million |
| Net loss | $9.73 million | $6.73 million |
| Cash used in operations | $3.17 million | $1.63 million |
| Cash at year-end | $5.93 million | $527 |
| Working capital | $5.34 million | Not stated |
| Total liabilities | $1.00 million | $5.27 million |
| Stockholders’ equity (deficit) | $6.41 million | $(4.16) million |
Margins are not meaningful because the company had no revenue. Fiscal 2014 interest expense included $2.92 million of amortized beneficial-conversion-feature discount and substantial amortization of debt discounts and financing costs. The company reported a $17.75 million accumulated deficit at June 30, 2014.
Changes versus prior year
- Net loss increased by about $3.00 million, primarily as interest expense rose by $3.66 million; operating expenses decreased by about $0.93 million.
- Operating cash use increased by about $1.54 million. Financing provided $9.93 million, including equity financing and convertible notes; the company ended the year with $5.93 million cash.
- Convertible debt and accrued interest were substantially converted into common stock during the year. At year-end, $60,000 of convertible notes remained outstanding; the filing says the matured notes were payable on demand and continued accruing interest.
- Shares outstanding rose to 18.09 million at June 30, 2014 from 6.67 million a year earlier. The company also had 11.10 million warrants outstanding at year-end, in addition to options.
Outlook, risks, and unusual items
- Management planned to complete IND-enabling preclinical work, file an IND in 2015, and begin a first clinical trial in the second half of 2015. These were plans, not achieved milestones. The filing reports promising prior preclinical findings, not human clinical evidence.
- Management estimated at least $10 million of additional financing would be needed through calendar year-end 2015. It cited monthly operating costs of roughly $350,000–$500,000, an estimated $2.5 million or more for facility improvements, about $1 million for equipment, and approximately $4 million for the planned first clinical study. Cash as of August 30, 2014 was reported at approximately $4.9 million.
- The independent auditor’s report and the filing identify substantial doubt about the company’s ability to continue as a going concern. The company had no products, no revenue, continuing losses, and depended on obtaining further financing; there was no assurance financing would be available on acceptable terms.
- The company leased a 27,000-square-foot facility for 72 months and reported minimum future rental commitments of approximately $2.10 million. It also disclosed up to $44 million of contingent consideration tied to AB101 development, licensing, regulatory approval, and sales milestones; no milestone payments had been triggered by the report date.
- Key risks include clinical, regulatory, manufacturing and supply uncertainty; competition from established insulin products and better-capitalized companies; patent and reimbursement uncertainty; potential dilution; and limited trading liquidity. The company’s stock was quoted on OTCQB.
- Management found material weaknesses in internal control over financial reporting, including inadequate segregation of duties, insufficient safeguards against override by the chief accounting officer, and inadequate controls for complex transactions. Management reported disclosure controls effective, but internal control over financial reporting was not effective.
Most important facts for investors to verify
- Confirm the issuer and period: the supplied document identifies AntriaBio, Inc. and fiscal 2014, not Rezolute, Inc. or 2013 Q4.
- Check the latest cash balance, subsequent financing, and whether the company obtained the additional capital needed to execute its clinical and facility plans.
- Verify the status and timing of AB101’s preclinical studies, IND filing, manufacturing readiness, and any clinical trials; the timelines in this filing were forward-looking expectations.
- Review the full financial statements and debt, warrant, option, and share-count disclosures for dilution and remaining obligations, including matured notes payable on demand.
- Assess progress in remediating the reported internal-control material weaknesses and review any subsequent auditor or company updates on going concern.
- Confirm the terms and potential impact of lease commitments, related-party arrangements, and the contingent PR Pharmaceuticals asset-purchase payments.